Ralinepag Phase II Open-Label Extension Study in Patients with Pulmonary Arterial Hypertension.

Ralinepag produced sustained, durable improvements in 6MWD along with durable reductions in PVR and a manageable AE profile. Most participants continuing treatment with ralinepag maintained functional measures throughout the OLE and those switching from placebo to ralinepag often experienced functional improvements.